AIDS Treatment News logo      

July 26, 2009

People on Sustiva Have Less Risk for Treatment Failure Than People on Kaletra

"People taking a regimen containing efavirenz (found in Sustiva and Atripla) appear to have less chance of virologic failure on treatment than people on a regimen including lopinavir/ritonavir (Kaletra), no matter their initial CD4 count. The study was presented at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town by Heiner Bucher, MD, MPH, from the University Hospital Basel in Switzerland. The study adds another voice to a chorus of conflicting previous studies comparing the two treatments."

Read more in POZ, July 22, 2009.